A Review for Emergency Providers

Emergency Medicine Clinics of North America

Volumn 33, Issue 2, 2015, Pages e1-e18

  Torres, Mercedes ^a   Hansen, Karen N ^a   Jerrard, David ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Ebola; Emergency department; Filovirus; Zaire ebolavirus

Indexed keywords

CAD3 VACCINE; DNA VACCINE; EBOLA VACCINE; MONOCLONAL ANTIBODY; RECOMBINANT VESICULAR STOMATITIS VIRUS VACCINE; UNCLASSIFIED DRUG; ZMAPP;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DISEASE TRANSMISSION; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EMERGENCY CARE; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; FILOVIRUS; FLUID RESUSCITATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; INFECTION CONTROL; NONHUMAN; PATIENT CARE; PATIENT DECISION MAKING; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; REHYDRATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS TRANSMISSION; EMERGENCY MEDICINE; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; ORGANIZATION AND MANAGEMENT; PROCEDURES; PROTECTIVE CLOTHING;

DISEASE OUTBREAKS; EBOLA VACCINES; EBOLAVIRUS; EMERGENCY MEDICAL SERVICES; EMERGENCY MEDICINE; HEMORRHAGIC FEVER, EBOLA; HUMANS; PATIENT ISOLATION; PROTECTIVE CLOTHING;

EID: 84931840314     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.emc.2014.12.001     Document Type: Review

References (77)

1. Smith CE, Simpson DI, Bowen ET, et al. Fatal human disease from vervet monkeys. Lancet 1967;2(7526):1119-21.
2. Slenczka W, Klenk H. Forty years of marburg virus. J Infect Dis 2007;196(Suppl 2):S131-5.
3. Breman JG, Johnson KM. Ebola then and now. N Engl J Med 2014;371(18): 1663-6.
4. Johnson KM, Lange JV, Webb PA, et al. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1977;1(8011):569-71.
5. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 2011;17(7):964-76.
6. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014;371(15):1418-25.
7. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 2014;345(6202): 1369-72.
8. Vogel G. Infectious Disease. Genomes reveal start of Ebola outbreak. Science 2014;345(6200):989-90.
9. World Health Organization Ebola Response Team. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 2014;371(16):1481-95.
10. Chevalier MS, Chung W, Smith J, et al. Ebola virus disease cluster in the United States -Dallas county, Texas, 2014. MMWR Morb Mortal Wkly Rep 2014;63(46): 1087-8.
11. Kuhn JH, Becker S, Ebihara H, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010;155(12):2083-103.
12. Miranda ME, Miranda NL. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 2011;204(Suppl 3):S757-60.
13. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 1409-48.
14. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377(9768): 849-62.
15. Basler CF, Wang X, Muhlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 2000;97(22):12289-94.
16. Reid SP, Leung LW, Hartman AL, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006;80(11):5156-67.
17. Sanchez A, Trappier SG, Mahy BW, et al. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 1996;93(8):3602-7.
18. Li YH, Chen SP. Evolutionary history of Ebola virus. Epidemiol Infect 2014;142(6): 1138-45.
19. Suzuki Y, Gojobori T. The origin and evolution of Ebola and Marburg viruses. Mol Biol Evol 1997;14(8):800-6.
20. Carroll SA, Towner JS, Sealy TK, et al. Molecular evolution of viruses of the family Filoviridae based on 97 whole-genome sequences. J Virol 2013;87(5):2608-16.
21. Taylor DJ, Leach RW, Bruenn J. Filoviruses are ancient and integrated into mammalian genomes. BMC Evol Biol 2010;10:193.
22. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438(7068):575-6.
23. Pourrut X, Delicat A, Rollin PE, et al. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis 2007;196(Suppl 2):S176-83.
24. Swanepoel R, Leman PA, Burt FJ, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 1996;2(4):321-5.
25. Kuzmin IV, Niezgoda M, Franka R, et al. Marburg virus in fruit bat, Kenya. Emerg Infect Dis 2010;16(2):352-4.
26. Olson SH, Reed P, Cameron KN, et al. Dead or alive: animal sampling during Ebola hemorrhagic fever outbreaks in humans. Emerg Health Threats J 2012;5:9134.
27. Burd EM. Ebola Virus: a clear and present danger. J Clin Microbiol 2015;53(1): 4-8.
28. U.S. Occupational Safety and Health Administration. OSHA FactSheet: cleaning and decontamination of Ebola on surfaces. 2014. Available at: https://www.osha. gov/Publications/OSHA_FS-3756.pdf. Accessed December 2, 2014.
29. Sagripanti JL, Lytle CD. Sensitivity to ultraviolet radiation of Lassa, vaccinia, and Ebola viruses dried on surfaces. Arch Virol 2011;156(3):489-94.
30. Elliott LH, McCormick JB, Johnson KM. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol 1982;16(4):704-8.
31. Piercy TJ, Smither SJ, Steward JA, et al. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J Appl Microbiol 2010;109(5):1531-9.
32. Sagripanti JL, Rom AM, Holland LE. Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces. Arch Virol 2010;155(12):2035-9.
33. Toner E, Adalja A, Inglesby T. A primer on Ebola for clinicians. Disaster Med Public Health Prep 2014;1-5 [Epub ahead of print].
34. U.S. Centers for Disease Control and Prevention. Ebola virus disease information for clinicians in US healthcare settings. 2014. Available at: http://www.cdc.gov/vhf/ebola/hcp/clinician-information-us-healthcare-settings.html. Accessed October 31, 2014.
35. Meyers L, Frawley T, Goss S, et al. Ebola virus outbreak 2014: clinical review for emergency physicians. Ann Emerg Med 2014;65(1):101-8.
36. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999;179(Suppl 1):S177-87.
37. Leroy EM, Baize S, Lu CY, et al. Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol 2000;60(4):463-7.
38. Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004;78(8):4330-41.
39. U.S. Centers for Disease Control and Prevention. Interim guidance for specimen collection, transport, testing, and submission for persons under investigation for Ebola Virus Disease in the United States. 2014. http://www.cdc.gov/vhf/ebola/index.html. Accessed December 5, 2014.
40. U.S. Food and Drug Administration. Emergency preparedness and response: emergency use authorization/Ebola Virus EUA information. 2014. http://www. fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMLegalRegulatoryandPolicyFramework/ucm182568.htm#ebola. Accessed December 2, 2014.
41. Iwen PC, Garrett JL, Gibbs SG, et al. An integrated approach to laboratory testing for patients with ebola virus disease. Lab Med 2014;45(4):e146-51.
42. Vogel G. Infectious diseases. Testing new Ebola tests. Science 2014;345(6204): 1549-50.
43. U.S. Centers for Disease Control and Prevention. Review of human-to-human transmission of Ebola Virus. 2014. Available at: http://www.cdc.gov/vhf/ebola/transmission/human-transmission.html. Accessed November 23, 2014.
44. Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999;179(Suppl 1):S28-35.
45. U.S. Centers for Disease Control and Prevention. Guidance on personal protective equipment to be used by healthcare workers during management of patients with Ebola Virus Disease in U.S. Hospitals, Including procedures for putting on (Donning) and removing (Doffing). 2014. Available at: http://www.cdc.gov/vhf/ebola/hcp/procedures-for-ppe.html. Accessed November 23, 2014.
46. World Health Organization. Personal Protective Equipment in the Context of Filovirus Disease Outbreak Response. World Health Organization; 2014. Available at: http://www.who.int/csr/resources/publications/ebola/ppe-guideline/en/. Accessed November 23, 2014.
47. World Health Organization. Personal protective equipment (PPE) in the context of filovirus disease outbreak response Technical specifications for PPE equipment to be used by health workers providing clinical care for patients. World Health Organization; 2014. Available at: http://www.who.int/csr/resources/publications/ebola/ppe-guideline/en/. Accessed November 23, 2014.
48. U.S. Centers for Disease Control and Prevention. Identify, isolate, inform: Emergency Department Evaluation and Management for patients who present with possible Ebola virus disease 2014. Available at: http://www.cdc.gov/vhf/ebola/hcp/ed-management-patients-possible-ebola.html. Accessed November 23, 2014.
49. Bah EI, Lamah M-C, Fletcher T, et al. Clinical presentation of patients with Ebola Virus Disease in Conakry, Guinea. N Engl J Med 2014;.www. NEJM.org [Epub ahead of print]. Accessed November 11, 2014.
50. Lamontagne F, Clément C, Fletcher T, et al. Doing today's work superbly well - treating Ebola with current tools. N Engl J Med 2014;371(17):1565-6.
51. U.S. Centers for Disease Control and Prevention. Interim U.S. guidance for monitoring and movement of persons with potential Ebola virus exposure. Available at: http://www.cdc.gov/vhf/ebola/exposure/monitoring-andmovement-of-persons-with-exposure.html. Accessed November 23, 2014.
52. U.S. Centers for Disease Control and Prevention. Interim guidance for emergency medical services (EMS) systems and 9-1-1 public safety answering points (PSAPs) for management of patients with known or suspected Ebola Virus Disease in the United States. 2014. Available at: http://www.cdc.gov/vhf/ebola/hcp/interim-guidance-emergency-medical-services-systems-911-public-safetyanswering-points-management-patients-known-suspected-united-states.html. Accessed November 23, 2014.
53. U.S. Centers for Disease Control and Prevention. Legal authorities for isolation and quarantine. 2014. Available at: http://www.cdc.gov/quarantine/aboutlaws regulationsquarantineisolation.html. Accessed November 24, 2014.
54. Gostin LO. The Model State Emergency Health Powers Act (MSEHPA). In: The center for law and the Public's Health at Georgetown and Johns Hopkins Universities. Washington, DC: Center for Law and the Public's Health; 2001. p. 1-39.
55. Francesconi P, Yoti Z, Declich S, et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 2003;9:1430-7.
56. Canadian Critical Care Society, Canadian Association of Emergency Physicians, Association of of Medicial Microbiology & Infectious Diseases Canada. Ebola clinical care guidelines. Interim report. 2014. Available at: http://www.ammi.ca/media/69846Ebola%20Clinical%20Care%20Guidelines%202%20Sep%202014.pdf. Accessed October 29, 2014.
57. Colebunders R, Tshomba A, Van Kerklose M, et al. Marburg hemorrhagic fever in Durba and Watson, Democratic Republic of the Congo: clinical documentation, features of illness and the treatment. J Infect Dis 2007;196:S148-53.
58. Clark D, Jahrling P, Lawler J. Clinical management of filovirus-infected patients. Viruses 2012;4(9):1668-86.
59. Bray M, Paragas J. Experimental therapy of filovirus infections. Antiviral Res 2002;54(1):1-17.
60. Parren P, Geisbert T, Marayama T, et al. Pre-and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002;76:6408-12.
61. Gulland A. First Ebola treatment is approved by WHO. BMJ 2014;349:g5539.
62. McCarthy M. US signs contract with ZMAPP maker to accelerate development of the Ebola drug. BMJ 2014;349:g5488.
63. Goodman J. Studying "secret serums"-toward safe, effective Ebola treatment. N Engl J Med 2014;371:1086-9.
64. U.S. Centers for Disease Control and Prevention. Considerations for discharging persons under investigation (PUI) for Ebola Virus Disease (Ebola). 2014. Available at: http://www.cdc.gov/vhf/ebola/hcp/considerations-discharging-pui.html. Accessed November 23, 2014.
65. Kortepeter MG, Martin JW, Rusnak JM, et al. Managing potential laboratory exposure to Ebola Virus by using a patient biocontainment care unit. Emerg Infect Dis 2008;14(6):881-7.
66. Cohen J. Ebola vaccines racing forward at record pace. Science 2014;345: 1228-9.
67. Lupton H, Lambert R, Baumgardner D, et al. Inactivated vaccine for Ebola virus efficacy in guinea pig model. Lancet 1980;2:1294-5.
68. Vanderzanden L. DNA vaccine expressing either the GP or NP genes of Ebola protect mice from lethal challenge. Virology 1998;246:134-44.
69. Baskerville A, Bowen E, Platt G, et al. The pathology of experimental Ebola virus infection in monkeys. J Pathol 1978;125(3):131-8.
70. Fausther-Bovendo H, Mulangu S, Sullivan N. Ebolavirus for humans and apes. Curr Opin Virol 2012;2(3):324-9.
71. Feldman H. Effective post-exposure treatment of Ebola infection. PLoS Pathol 2007;3:e2.
72. Pratt W, Wang D, Nichols D, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010;17(4):572-81.
73. Fauci A. Ebola-underscoring the global disparities in health care resources. N Engl J Med 2014;371(12):1084-6.
74. Geisbert T, Geisbert J, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009;83:7296-304.
75. Stanley D, Honko A, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebolavirus challenge. Nat Med 2014;20(10):1126-9.
76. Hoenen T, Groseth A, Feldman H. Current Ebola vaccines. Expert Opin Biol Ther 2012;12(7):859-72.
77. Butler D. WHO plans for millions of doses of Ebola vaccine by 2015. Nature 2014.